Cases
MedEquities Realty Trust, Inc. (MRT)
Merger
Overview
Overview
- Date:
- 1/2/2019
- Company Name:
- MedEquities Realty Trust, Inc.
- Stock Symbol:
- MRT
- Company Name - Buyer:
- Omega Healthcare Investors, Inc.
- Stock Symbol - Buyer:
- OHI
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/2/2019
NEW YORK, January 2, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of MedEquities Realty Trust, Inc. (NYSE: MRT) on behalf of stockholders concerning the proposed acquisition of the company by Omega Healthcare Investors, Inc. (NYSE: OHI).
Pursuant to the proposed transaction, announced on January 2, 2019, MedEquities stockholders will receive 0.235 shares of Omega and $2.00 in cash for each share of MedEquities common stock owned. Separately, MedEquities will declare a special cash dividend of $0.21 per share payable to the holders of record of MedEquities common stock as of the end of trading on the New York Stock Exchange on the trading day immediately prior to the closing date of the transaction. The investigation focuses on whether MedEquities and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own MedEquities shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on January 2, 2019, MedEquities stockholders will receive 0.235 shares of Omega and $2.00 in cash for each share of MedEquities common stock owned. Separately, MedEquities will declare a special cash dividend of $0.21 per share payable to the holders of record of MedEquities common stock as of the end of trading on the New York Stock Exchange on the trading day immediately prior to the closing date of the transaction. The investigation focuses on whether MedEquities and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own MedEquities shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.